GGrantIndex
← Leaderboards

Lisa A Maier

National Jewish Health

$11,952,941
Attributed
$24,262,935
Total exposure
26
Grants
18
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$26,894,566 · 27

By mechanism

R01$17,076,223 · 7
P01$4,837,392 · 4
T32$3,642,169 · 1
U01$464,725 · 1
R21$442,546 · 1
K08$334,854 · 1

Top collaborators

Most similar at National Jewish Health

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungGranulomatousLung DiseasesImmune ResponseFutureGenesPathway InteractionsCellsBerylliumGeneticGranulomaCytokineInflammationBiological MarkersBaseSamplingImmuneCd4 Positive T LymphocytesChronic BerylliosisAntigensT-LymphocyteBronchoalveolar LavageDisorder RiskGene Expression

Grant awards (64)

Multi-Disciplinary Research Training in Respiratory Disease$1,163,358
T32 · FY2025 · HL
Molecular Characterization of Progressive Pulmonary Sarcoidosis$784,774
R01 · FY2025 · HL · contact PI
Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium Disease$636,949
R01 · FY2025 · ES · contact PI
Molecular Characterization of Progressive Pulmonary Sarcoidosis$772,729
R01 · FY2024 · HL · contact PI
Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis$690,310
R01 · FY2024 · HL
Multi-Disciplinary Research Training in Respiratory Disease$670,419
T32 · FY2024 · HL
Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium Disease$646,640
R01 · FY2024 · ES · contact PI
Multi-Disciplinary Research Training in Respiratory Disease$1,084,763
T32 · FY2023 · HL
Molecular Characterization of Progressive Pulmonary Sarcoidosis$826,678
R01 · FY2023 · HL · contact PI
Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis$700,508
R01 · FY2023 · HL
Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium Disease$647,711
R01 · FY2023 · ES · contact PI
Multi-Disciplinary Research Training in Respiratory Disease$723,629
T32 · FY2022 · HL
Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis$700,327
R01 · FY2022 · HL
Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium Disease$659,638
R01 · FY2022 · ES · contact PI
Novel integrative approaches for disease phenotyping, utilizing radiomics in Sarcoidosis$633,593
R01 · FY2022 · HL
Aspen Lung Conference: Bridging the Gap between Innate and Adaptive Immunity in the Lung$33,000
R13 · FY2022 · HL · contact PI
Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis$699,474
R01 · FY2021 · HL
Epigenetic Regulation of Immune Pathways in Sarcoidosis$697,552
R01 · FY2021 · HL · contact PI
Novel integrative approaches for disease phenotyping, utilizing radiomics in Sarcoidosis$628,515
R01 · FY2021 · HL
Epigenetic Regulation of Immune Pathways in Sarcoidosis$699,263
R01 · FY2020 · HL · contact PI
Novel integrative approaches for disease phenotyping, utilizing radiomics in Sarcoidosis$649,128
R01 · FY2020 · HL
Epigenetic Regulation of Immune Pathways in Sarcoidosis$688,427
R01 · FY2019 · HL · contact PI
Novel integrative approaches for disease phenotyping, utilizing radiomics in Sarcoidosis$655,027
R01 · FY2019 · HL
Exposure in Epigenetic Regulation of Immune Response in CBD$466,884
R01 · FY2019 · ES · contact PI
Epigenetic Regulation of Immune Pathways in Sarcoidosis$712,638
R01 · FY2018 · HL · contact PI
Exposure in Epigenetic Regulation of Immune Response in CBD$482,240
R01 · FY2018 · ES · contact PI
Exposure in Epigenetic Regulation of Immune Response in CBD$448,525
R01 · FY2017 · ES · contact PI
Aspen Lung Conference: Environment and Global Lung Health, Susceptibility, and Intervention$30,000
R13 · FY2017 · HL · contact PI
Exposure in Epigenetic Regulation of Immune Response in CBD$437,315
R01 · FY2016 · ES · contact PI
Exposure in Epigenetic Regulation of Immune Response in CBD$425,671
R01 · FY2015 · ES · contact PI
Immunologic and Molecular Phenotypes in AATD and Sarcoidosis$155,331
U01 · FY2014 · HL · contact PI
Project 2 - Immunogenetic and Exposure Factors in Berylliosis$420,774
P01 · FY2013 · ES · contact PI
Targeting Oxidative Stress in Chronic Beryllium Disease$336,590
R01 · FY2013 · ES
Immunologic and Molecular Phenotypes in AATD and Sarcoidosis$150,894
U01 · FY2013 · HL · contact PI
Project 2 - Immunogenetic and Exposure Factors in Berylliosis$423,098
P01 · FY2012 · ES · contact PI
Targeting Oxidative Stress in Chronic Beryllium Disease$339,878
R01 · FY2012 · ES
Immunologic and Molecular Phenotypes in AATD and Sarcoidosis$158,500
U01 · FY2012 · HL · contact PI
Project 2 - Immunogenetic and Exposure Factors in Berylliosis$438,831
P01 · FY2011 · ES · contact PI
Targeting Oxidative Stress in Chronic Beryllium Disease$336,403
R01 · FY2011 · ES
Project 2 - Immunogenetic and Exposure Factors in Berylliosis$448,544
P01 · FY2010 · ES · contact PI
Targeting Oxidative Stress in Chronic Beryllium Disease$336,391
R01 · FY2010 · ES
Project 2 - Immunogenetic and Exposure Factors in Berylliosis$474,514
P01 · FY2009 · ES · contact PI
Targeting Oxidative Stress in Chronic Beryllium Disease$336,445
R01 · FY2009 · ES
Shared Genetic Susceptibility in CBD and Sarcoidosis$160,133
R21 · FY2008 · HL · contact PI
Beryllium: Exposure, Immune and Genetic Mechanisms$109,289
P01 · FY2008 · ES · contact PI
USE OF SPUTUM AND ENVIRONMENTAL TESTING FOR CBD SURVEILLANCE AND MONITORING$1,187
M01 · FY2008 · RR · contact PI
CLINICAL EFFICACY OF REMICADE IN CBD$554
M01 · FY2008 · RR · contact PI
BERYLLIUM RESEARCH PROGRAM, PROJECT 1$237
M01 · FY2008 · RR · contact PI
BERYLLIUM RESEARCH PROGRAM, PROJECT 2$119
M01 · FY2008 · RR · contact PI
Shared Genetic Susceptibility in CBD and Sarcoidosis$282,413
R21 · FY2007 · HL · contact PI
CLINICAL EFFICACY OF REMICADE IN CBD$16,158
M01 · FY2007 · RR · contact PI
BERYLLIUM RESEARCH PROGRAM, PROJECT 2$1,683
M01 · FY2007 · RR · contact PI
BERYLLIUM RESEARCH PROGRAM, PROJECT 1$1,683
M01 · FY2007 · RR · contact PI
Beryllium: Exposure, Immune and Genetic Mechanisms$1,254,402
P01 · FY2006 · ES · contact PI
APOPTOSIS-RELATED GENETIC POLYMORPHISMS IN SARCOIDOSIS$5,570
M01 · FY2006 · RR · contact PI
BERYLLIUM RESEARCH PROGRAM, PROJECT 2$1,857
M01 · FY2006 · RR · contact PI
Beryllium: Exposure, Immune and Genetic Mechanisms$1,267,940
P01 · FY2005 · ES
BERYLLIUM RESEARCH PROGRAM, PROJECT 2$3,146
M01 · FY2005 · RR
Beryllium Research Program, Project 2$1,463
M01 · FY2004 · RR
LOCAL ANGIOTENSIN SYSTEM IN LUNG FIBROGENESIS$111,618
K08 · FY2002 · HL
CORE--Clinical Core$0
P01 · FY2002 · ES
Immunogenetic and Exposure Factors in Berylliosis$0
P01 · FY2002 · ES
LOCAL ANGIOTENSIN SYSTEM IN LUNG FIBROGENESIS$111,618
K08 · FY2001 · HL
LOCAL ANGIOTENSIN SYSTEM IN LUNG FIBROGENESIS$111,618
K08 · FY2000 · HL